Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs
Open Access
- 9 May 2005
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (9) , 978-984
- https://doi.org/10.1001/archinte.165.9.978
Abstract
The withdrawal of rofecoxib based on an increased risk of myocardial infarction (MI) and stroke among patients treated for longer than 18 months in the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial marks a dramatic event in the history of the cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).1 This has further been underscored by the decision by the US National Cancer Institute to halt the ongoing Adenoma Prevention with Celecoxib (APC) trial owing to increased cardiovascular risk among patients receiving celecoxib.2Keywords
This publication has 27 references indexed in Scilit:
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- A coxib a day won't keep the doctor awayThe Lancet, 2004
- COX‐2 selective non‐steroidal anti‐inflammatory drugs and cardiovascular diseasePharmacoepidemiology and Drug Safety, 2002
- Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial InfarctionArchives of internal medicine (1960), 2002
- Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.Archives of internal medicine (1960), 2002
- Association between naproxen use and protection against acute myocardial infarction.Archives of internal medicine (1960), 2002
- Cardiovascular Thrombotic Events in Controlled, Clinical Trials of RofecoxibCirculation, 2001
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000